<DOC>
	<DOCNO>NCT00912483</DOCNO>
	<brief_summary>The Venous thromboembolism ( VTE ) disease frequent , mainly complications medical disease surgical procedure . It high prevalence lead severe complication pulmonary embolism postthrombotic syndrome . Although incidence decrease recent year , EP DVT still major public health problem , especially advanced age . The track disease image test asymptomatic patient seem cost-effective , treatment complication expensive subject satisfactory answer completely effective regard late complication . Therefore , accord CAIAFA &amp; BASTOS ( 2002 ) , effective prophylaxis best strategy . The type prevention use base risk develop VTE , ie low , medium high . Framework category risk indication prophylaxis , patient evaluate individually carefully risk develop VTE . Maffei et al . ( 2005 ) describe `` Standards Clinical Guideline prevention , diagnosis treatment deep vein thrombosis . '' According guide , concentration heparin 5.000UI indicated case moderate-risk surgery . Are classified `` moderate risk '' surgery ( general , gynecological urological ) patient 40 60 year without additional risk factor , magnitude surgery patient 40 year age use estrogen ( Annex 01 ) . The dosing schedule chosen study also follow recommendation guide universally use . According Maffei et al . ( 2005 ) , diagnosis VTE must initiate history physical examination , must perform ultrasound Doppler low limb . Thus , ultra-sonography/doppler examination do begin end treatment physical examination do periodically throughout period monitoring . Following guideline propose literature consult , establish test methodology , aim demonstrate non inferiority clinical heparin sodium 5.000UI / 0.25 mL sodium heparin 5.000UI / 1.0 mL , produce Blausiegel Industry Trade Ltda . reduce incidence VTE . The two formulation produce material , different drug concentration . Thus , need scientifically prove therapeutic activity safety product test non-inferior comparator drug ( APP heparina - 5.000 USP/mL ) , allow sponsor company obtain registration product concentration 5000UI /0.25 mL ANVISA propose therapeutic indication study .</brief_summary>
	<brief_title>Efficacy Sodium Heparin Prophylaxis Venous Thromboembolism Surgical Patients</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Accept item describe Informed Consent , sign two way ; Age 40 60 year without additional risk factor , hold surgery ( general , gynecological urological ) ; Women age 18 40 year make use estrogen ; Be alert need surgery antithrombotic prophylaxis ; Be classify `` moderate risk '' develop VTE , accord protocol prophylaxis deep vein thrombosis Brazilian Society Angiology Vascular Surgery . Acute coronary syndrome ; Immobilization low limb due fracture , way consider high risk ; history recent stroke ; Patients high risk bleeding use heparin contraindicate ; General Surgery patient 60 year case patient high risk VTE ; general surgery patient 40 60 year additional risk factor development VTE ; Major amputation ; orthopedic surgery ; Patients presurgical diagnosis malignant neoplasm ; Patients platelet level 100x109 / L ; Use anticoagulants 48 hour randomization ; severe liver failure ; Be classify `` Low Risk '' `` high risk '' develop VTE Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>VTE</keyword>
</DOC>